Our previous study detected totally 35 CYP2C9 allelic variants in 2127 Chinese subjects, of whom 21 novel alleles were reported for the first time in Chinese populations. The aim of the present study was to characterize the 13 CYP2C9 allelic variants both in vitro and in vivo. Different types of CYP2C9 variants were highly expressed in COS-7 cells, and 50 mM tolbutamide was added as the probing substrate to evaluate their metabolic abilities in vitro. Subsequently, the concentrations of tolbutamide and its metabolite in the plasma and urine within individuals with different types of genotypes were determined by HPLC to evaluate the catalytic activity of the 13 mutant CYP2C9 proteins in vivo. Our results showed that compared with *1/*1 wild-type subjects, subjects with *1/*40 genotype showed increased oral clearance (CL/F), whereas individuals with
Introduction
The cytochrome P450 superfamily, officially abbreviated as CYP, is a group of enzymes mainly localized in the liver and intestinal tract, and it is responsible for the metabolism of many endogenous hormones and xenobiotic substances, including drugs and toxins. CYP2C9, making up about 20% CYP proteins in the human liver, is a major member of the CYP subfamily and is responsible for the metabolism of approximately 15% clinically used drugs (Rendic, 2002; Van Booven et al., 2010) .
Human CYP2C9 has been shown to exhibit genetic polymorphism since the discovery of the first allelic variant in 1970s. To date, more than 58 nonsynonymous variants and a series of subvariants of CYP2C9 have been reported (see http://www.imm.ki.se/CYPalleles; access date: Nov. 2014). CYP2C9*2 (430T.C Arg 144 Cys) and CYP2C9*3 (1075A.C Ile 359 Leu) are the most commonly investigated defective alleles, including the characterization of enzymatic activity in vivo and in vitro and population distribution data (García-Martín et al., 2001; Takahashi et al., 2003; Scordo et al., 2004; Scott et al., 2007; Silan et al., 2012; Kraj cíová et al., 2014) . Different populations had different frequencies of CYP2C9*2 and CYP2C9*3. For instance, in Chinese Han population, CYP2C9*1, CYP2C9*2, and CYP2C9*3 had a frequency of 0.963, 0.001, and 0.036 (Yang et al., 2003) , whereas in Italian and Ethiopian population, the corresponding frequencies were 0.8, 0.11, 0.09, and 0.94, 0.04, 0.02 (Scordo et al., 2001) , respectively. CYP2C9*13 was first discovered in Chinese Han population by Si et al. (2004) and was reported to have a frequency of 0.02% in Chinese. Thereafter, a series of investigations into the catalytic activity of CYP2C9*13 in vivo and in vitro were subsequently performed using tolbutamide, diclofenac, and lornoxicam as the probing substrates (Guo et al., 2005a (Guo et al., , 2005b . Moreover, genetic and clinic investigations in Korea had suggested that the presence of CYP2C9*13 allele statistically resulted in the poor metabolism of losartan and irbesartan after a single oral dose (Li et al., 2009; Choi et al., 2012) , and also influenced the pharmacokinetics and pharmacodynamics of meloxicam (Bae et al., 2011) .
CYP2C9*16(T299A) and CYP2C9*19(Q454H) were discovered after studying 125 Asians from Singapore (Zhao et al., 2004) . In vitro study showed that CYP2C9*16 exhibited 80-90% lower catalytic activity of tolbutamide, whereas CYP2C9*19 exhibited 30-40% lower catalytic activity of tolbutamide, when compared with wild-type CYP2C9*1, CYP2C9*27, and CYP2C9*29 discovered in 263 Japanese individuals (DeLozier et al., 2005) . Michaelis-Menten curves for diclofenac 4hydroxylation from recombinant microsomes showed the identical Km and Vmax values of CYP2C9*27and CYP2C9*29 compared with the wild-type (Maekawa et al., 2006) . CYP2C9*34(R335Q) was discovered after studying 724 Japanese individuals, including 39 hypertensive patients under treatment with losartan when compared with the wild-type (Maekawa et al., 2006) . When expressed in a baculovirus-insect cell system, CYP2C9*34 had no substantial effect. A study on substratedependent functional alteration of CYP2C9 demonstrated that CYP2C9*34 exhibited catalytic activities almost similar to those of the wild-type for diclofenac, losartan, and glimepiride (Maekawa et al., 2009) .
In our previous study, we sequenced all nine exons of CYP2C9 in 2127 nonrelated individuals, and found 21 novel CYP2C9 allelic variants (CYP2C9*36-*56) besides 14 previously reported allelic variants, of whom allelic variants (CYP2C9*3, CYP2C9*13, CYP2C9*16, CYP2C9*19, CYP2C9*27, CYP2C9*29, and CYP2C9*34) had highest gene frequencies in Chinese population (Dai et al., 2014b) . In this study, we comprehensively characterized the catalytic activities of above seven reported CYP2C9 alleles and six newly found allelic variants (CYP2C9*40, CYP2C9*41, CYP2C9*42, CYP2C9*45, CYP2C9*46, and CYP2C9*48) both in vitro and in vivo, aiming at confirming the consistency of in vitro and in vivo study as well.
Materials and Methods

Pharmaceutical Preparation and Reagents
Tolbutamide and 4-hydroxytolbutamide were purchased from Sigma-Aldrich (St. Louis, MO). Carboxytolbutamide was purchased from Toronto Research Chemicals (North York, Canada). Carbamazepine was purchased from the National Institute for Food and Drug Control (Beijing, China). Tolbutamide tablets were purchased from the Second Affiliated Hospital of Wenzhou Medical School. All other reagents were analytical grade.
Construction of Dual-Expression Plasmid. Construction of dual-expression plasmid was performed, as described previously (Dai et al., 2014b) . In brief, the intact Gaussia princeps luciferase (Gluc) open reading frame (ORF) was amplified from the pGluc-Basic plasmid (New England Biolabs, Ipswitch, MA) using the Gluc-XF (introducing one XbaI site) and Gluc-NR (introducing one NotI site) primers. The amplicon was purified and doubly digested with the XbaI and NotI enzymes and ligated to the XbaI/NotI site of the pIRES vector (Clontech, Mountain View, CA) to obtain recombinant receptor plasmid pIRES-Gluc. To introduce one nucleotide mutation at the expected site, overlap extension polymerase chain reaction (PCR) amplification was performed using the wildtype CYP2C9 plasmid (a gift of Prof. S.-f. Zhou, University of South Florida) as a template, except for the starting coding mutation CYP2C9*36. The PCR products were then gel purified, pooled, and used as the template for the secondround amplification using the 2C9-XF and 2C9-ER primer pairs to obtain the complete ORF region of mutated CYP2C9. For amplification of the entire ORF regions of the wild-type *1 or novel allele *36, only one round of PCR was needed, using 2C9-XF or SCMF as the forward primer and 2C9-ER as the reverse primer. Detailed information on all primers used in the construction process was presented in our previous study (Dai et al., 2014b) . The entire cDNA ORF regions were purified and double digested with the XhoI and EcoRI enzymes and inserted into the XhoI/EcoRI site of the receptor plasmid pIRES-Gluc to obtain the final dual expression plasmid pIRES-Gluc-2C9.
Plasmid Transfection. Approximately 0.7 Â 10 5 cells/well were plated on a 6-well plate 1 day before transfection, and cells were grown to 80% confluency at the time of transfection. The next day, 400 ng individual dual-expression plasmids was transfected into the COS-7 cells using the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA), according to manufacturer's instructions.
In Vitro Catalytic Activities of Recombinant CYP2C9 Proteins. Fortyeight hours after transfection, cells were digested with trypsinogen and resuspended in 300 mL Dulbecco's modified eagle culture medium supplemented with 10% fetal bovine serum, 10,000 U/mL penicillin, 10,000 mg/mL streptomycin, and 50 mM tolbutamide [this concentration was selected based on its metabolic Km by the human liver microsomes (Tang et al., 2002) ]. The samples of various genotypes were cultured in suspension on a shaking table at 800 r.p.m. in a CO 2 incubator for 1 hour. The reactions were stopped by addition of 100 mL 0.1 M HCl, and 50 mL 20 mg/mL carbamazepine in the methanol as an internal standard was added into each tube. A total of 1 mL ethyl acetate was added for extraction. After centrifugation for 30 minutes at 13,000 r.p.m., the supernatant of organic phase was separated, and the organic phase was transferred to another tube and evaporated to dryness at 50°C under a gentle stream of nitrogen. The residue was dissolved in 100 mL mobile phase for analysis.
Protein Expression Quantification by Western Blotting. Cells in each well were lysed in lysis buffer containing 50 mM Tris-HCl (pH 7.6), 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% Nonidet P-40, 0.01 mg/ml aprotinin, and 1 mM phenylmethanesulfonyl fluoride. Twenty micrograms of the total cellar lysates was applied to 12% SDS-PAGE and electrotransferred onto polyvinylidene difluoride membranes. Rabbit polyclonal anti-CYP2C9 antibody (AbD Serotec, Puchheim, Germany), rabbit polyclonal anti-Gluc antibody (New England Biolabs), or rabbit monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase antibody (Abmart, Shanghai, China) was used as the primary antibody at 1:5000. After incubation at 4°C overnight, goat anti-rabbit IgG horseradish peroxidaseconjugated antibody at 1:2000 was applied as the secondary antibody, and the materials were incubated at room temperature for 1 hour. The Super Signal West Pico Trial Kit (Thermo, Rockford, IL) was used to visualize the blot signals.
Subjects and Sample Collecting. Twenty-eight healthy subjects with different genotypes, consisting of seven CYP2C9*1 homozygotes, seven CYP2C9*3 heterozygotes, one CYP2C9*3 homozygotes, seven subjects with identified variants, and six subjects with novel variants, aged 21;22 years, were enrolled in this study for identifying CYP2C9 enzymatic activities in vivo. The details were presented in Table 1 . All subjects were in good health and required to refrain from all medication and alcohol prior to the pharmacokinetic study. The study was approved by the Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical School, and all subjects signed informed consents before participating in the investigation.
The 28 healthy subjects received an oral administration of 500 mg tolbutamide after fasting for 12 hours. Blood samples were collected before dosage and 0.5, 1, 1. 5, 2.5, 4.5, 6, 9, 12, 24 , and 36 hours at least, followed by immediate centrifugation. The plasma was extracted to 1.5 mL tube and stored at 280°C till analysis. The 36-hour concentrations of tolbutamide in plasma samples were analyzed immediately. Subjects with high tolbutamide concentrations were required to continue sample collecting till the concentration level fell below the level of 6 mg/ml. The 75 g glucose was administered to subjects 0.5 hour postadministration of the drug. Plasma at the time points of 0-4.5 hours was monitored for glucose concentration as well. Urine samples of the subjects at periods of 0;6 hours, 6;12 hours, and 12;24 hours were collected in individuals for determination of 4-hydroxytolbutamide and carboxytolbutamide.
Sample Analysis. The concentrations of substrate and product in plasma were determined by high performance liquid chromatography, according to the method as described previously (Lin et al., 2012) . The urinary concentrations 
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were determined as above, except the mobile phrase. The first 8 minutes, solvent A reduced from 60% to 48%, whereas solvent B increased from 20% to 32%; the next 7 minutes, solvent A reduced from 48% to 16%, whereas solvent B increased from 32% to 64%. Solvent C maintained to be 20%. All compounds were detected at an optimum wavelength of 230 nm. Under these conditions, the retention times of 4-hydroxytolbutamide, carboxytolbutamide, and tolbutamide were 7.73, 9.114, and 14.15 minutes, respectively. Data Analysis. Percentage of enzymatic activity matching the wild-type was calculated to compare the catalytic activity of novel variants with that of CYP2C9*1/*1. Dunnett's test was used to analyze differences in catalytic activity in the mutant CYP2C9 group to a single control group (CYP2C9*1) for in vitro study. The plasma concentration-time profiles of tolbutamide and 4hydroxytolbutamide were evaluated by noncompartmental analysis. The area under the plasma concentration-time curve from time zero to infinity [AUC (0-') ], AUC (0-t) , the half-life (t 1/2 ), C max , and T max were calculated by DAS3.0 (Mathematical Pharmacology Professional Committee of China, Shanghai, China). The sum of amounts of metabolites excreted in urine over 24 hours postadministration was calculated. The Student t test was used to analyze pharmacokinetic and pharmacodynamic differences in catalytic activity between the CYP2C9*1/*1 and CYP2C9*1/*3 subjects. Statistical analyses were performed with the SPSS package (version 19.0; SPSS, Chicago, IL), with P , 0.05 considered to be statistically significant. The correlation between in vitro enzymatic activity and in vivo activity (t 1/2 ) was analyzed using a linear regression analysis program (GraphPad Software, San Diego, CA).
Results
In Vitro Study of Novel Alleles
When expressed in COS-7 cells, besides two typical defective alleles, CYP2C9*3 and CYP2C9*13, three allelic variants (CYP2C9*19, Fig. 1 . Expression efficacies of CYPs and their activities to hydroxylize tolbutamide. (A) Expression efficacies evaluated by Western blotting. The first line (COS-7) was transfected by the mock agent, and the expression efficacy was adjusted by the internal transfection control protein (Gaussia princeps luciferase, Glu). Glyceraldehyde-3-phosphate dehydrogenase is a housekeeping protein; (B) the relative tolbutamide hydroxylase activities of mutant CYP2C9 alleles in COS-7 cells were compared with that of wildtype CYP2C9*1 (as 100%). Significantly different from wild-type CYP2C9, *P , 0.05, **P , 0.01, respectively. Consequently, their corresponding catalytic activities significantly were impaired when tolbutamide was used as the probing substrate in our analytical system. In addition, five other CYP2C9 isoforms (CYP2C9*16, CYP2C9*42, CYP2C9*45, CYP2C9*46, and CYP2C9*48) exhibited impaired enzymatic activities compared with wild-type protein, although their protein expression levels were slightly influenced or comparable to that of wild-type enzyme. Remaining four variants had similar protein expression levels, but two variants (CYP2C9*29 and CYP2C9*40) showed higher catalytic activities toward tolbutamide, and the other two isoforms (CYP2C9*27 and CYP2C9*41) had similar characters to wildtype ( Fig. 1) . These data infer that most of the mutations in CYP2C9 genes could significantly affect the enzyme's catalytic activities toward tolbutamide in vitro ( Fig. 1 and Table 2 ). The In Vivo Effects of Novel Alleles on Concentrations of Tolbutamide and Its Hydroxyl Metabolites in Plasma. The pharmacokinetic parameters of AUC (0-') , AUC (0-t) , C max , t 1/2 , and oral clearance (CL/F) were calculated to functionally characterize the catalytic activities of CYP2C9 alleles, and the data were shown in Table 3 and 4; the concentration-time curve of tolbutamide and 4-hydroxytolbutamide was shown in Figs. 2, 3, and 4 .
In the present study, subjects with the genotype of CYP2C9*1/*3 and CYP 2C9*1/*13 had 1.78-fold and 2.81-fold increases in AUC 0→t as well as 1.69-fold and 2.08-fold increases in t 1/2 , respectively, whereas their CL/F values were decreased by 43% and 65%, respectively, when compared with subjects with genotype of CYP2C9*1/*1. AUC 0→t and t 1/2 of the individual with the genotype of CYP2C9*3/*3 were increased by 5.84-fold and 5.48-fold, respectively, whereas its CL/F was decreased by 86%. AUC 0→t and t 1/2 of the individual with the genotype of CYP2C9*3/*13 were increased by 8.06-fold and 6.07-fold, respectively, whereas its CL/F was decreased by 89%.
CYP2C9*16, CYP2C9*19, CYP2C9*27, CYP2C9*29, and CYP2C9*34 were five rare variants that had already been identified in Chinese Han population. Compared with the wild-type, subjects with genotype of CYP2C9*1/*16, CYP2C9*1/*19, and CYP2C9*34 showed 1.36-fold, 1.50-fold, and 1.90-fold increases in AUC 0→t and 1.51-fold, 1.31-fold, and 1.76-fold increases in t 1/2 , whereas the CL/F values were decreased by 28%, 35%, and 49%, respectively. The individual with the genotype of CYP2C9*1/*27 had 12% and 10% decrease in 
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AUC 0→t and t 1/2 , respectively, whereas the CL/F was increased by 11%. The individual with the genotype of CYP2C9*1/*29 had a very slight (1.05-fold and 1.02-fold) increase in AUC 0→t and t 1/2 , and the CL/F was also decreased slightly (7%). The data showed a serious impact on CYP2C9*34 enzymatic activity, whereas in the study of Yin et al. (2008) , a slight diminution in intrinsic clearance (6%) was observed for the CYP2C9*34 (Arg 335 Gln) protein with slightly decreased Km and Vmax values in in vitro investigation. CYP2C9*40, CYP2C9*41, CYP2C9*42, CYP2C9*45, CYP2C9*46, and CYP2C9*48 were the six novel variants found in our previous study (Dai et al., 2014b) . Compared with the wild-type, the individual with the genotype of CYP2C9*1/*40 had a 22% and 19% decrease in AUC 0→t and t 1/2 , whereas the CL/F was increased by 25%; the individual with the genotype of CYP2C9*1/*41 had 7% increase in AUC 0→t , whereas the t 1/2 and CL/F were decreased by 6% and 9%, showing a slight decrease in enzymatic activity (Table 3 ). The individuals with the genotype of CYP2C9*1/*42, *1/*45, *1/*46, and *1/*48 had 2.16-fold, 1.70-fold, 1.87-fold, and 3.29-fold increases in AUC 0→t and 1.95-fold, 1.65-fold, 1.47-fold, and 2.89-fold increases in t 1/2 , whereas the CL/F was decreased by 55%, 43%, 48%, and 70%, respectively. The results of 4-hydroxytolbutamide (as listed in Table 4 ) showed greater variability than tolbutamide in plasma.
In Vitro-In Vivo Correlation Analysis. Combining the in vitro and in vivo data together, good correlation (Fig. 5 ) was found between in vitro enzymatic activity and t 1/2 of tolbutamide in vivo when excluding the data of CYP2C9*48 (r 2 = 0.8031). These data infer that most of newly found mutated sites in CYP2C9 can significantly decrease the metabolic activity of CYPs and result in the longer t 1/2 time of tolbutamide for individuals carrying these novel alleles.
Concentration of Tolbutamide and Its Metabolites in Urine. The 0-to 24-hour urinary excretions of both metabolites were calculated and were shown in Fig. 6 . Significant decrease in urinary excretion of 
tolbutamide metabolites in the 0-to 24-hour interval was observed in individuals with the genotype of CYP2C9 *1/*3, compared with subjects expressing the CYP2C9*1/*1.
Pharmacodynamic Study. Before tolbutamide administration, there were no significant differences in serum glucose concentrations between the CYP2C9*1/*1 and CYP2C9*1/*3 subjects. The time course of serum glucose levels and delta glucose levels after oral administration of 75 g dextrose was presented in Fig. 7 . After tolbutamide administration, statistical significance of delta glucose concentration was only observed at time points of 0.5 hour and 4.5 hours.
Discussion
The present investigation provides comprehensive data on functional characters of 13 CYP2C9 allelic variants both in vitro and in vivo. The previous effort on the large-scale direct sequencing of CYP2C9 gene allowed us to discover 36 genetic variations in 2127
Chinese Han individuals. Volunteers in the present study included 16 different types of genotypes, as follows: CYP2C9*1/*1, CYP2C9*1/*3, CYP2C9*3/*3, CYP2C9*1/*13, CYP2C9*3/*13, CYP2C9*1/*16, CYP2C9*1/*19, CYP2C9*1/*27, CYP2C9*1/*29, CYP2C9*1/*34, CYP2C9*1/*40, CYP2C9*1/*41, CYP2C9*1/*42, CYP2C9*1/*45, CYP2C9*1/*46, and CYP2C9*1/*48.
In this study, tolbutamide, a first-generation sulphonylurea hypoglycemic drug, was selected as the probe substrate for determining CYP2C9 activity in vitro and in vivo. Tolbutamide is commonly chosen as the typical probing substrate for CYP2C9 enzyme both in vitro and in vivo, because it is primarily (78-93%) metabolized by hepatic CYP2C9 to 4-hydroxytolbutamide, which is further oxidized to carboxytolbutamide by alcohol dehydrogenase and excreted by kidney (Wester et al., 2000) . Although CYP2C19 also participated in tolbutamide metabolism, it has been stated that no pharmacokinetic and pharmacodynamic differences were found between CYP2C19 extensive metabolizer and poor metabolizer genotype subjects and tolbutamide was a selective probe for measuring CYP2C9 activity in humans (Shon et al., 2002) .
CYP2C9*3 and CYP2C9*13 are two defective alleles studied most in the Chinese population. Our data showed that both CYP2C9*3 and CYP2C9*13 alleles dramatically impaired catalytic activities of their CYP2C9 proteins. CYP2C9*3 carriers exhibited statistical significance on AUC, t 1/2 , and CL/F of tolbutamide and C max of 4-hydroxytolbutamide. Due to the fact that CYP2C9 alleles on two parallel chromosomes are both responsible for the expression of enzymes in vivo, then affection of the enzymatic deficiency on function in homozygote is far beyond that in heterozygous individual. In our study, concentrations of 4hydroxytolbutamide of the CYP2C9*3/*3 and CYP2C9*3/*13 subjects were lower than those of the CYP2C9*1/*1, CYP2C9*1/*3, and CYP2C9*1/*13 subjects. Si et al. (2004) reported that one individual with the genotype of CYP2C9*3/*13 had a 108-hour t 1/2 of tolbutamide, which was much longer than that (t 1/2 of 56.9 hours) discovered in our study. We believe that the longer monitoring time of drug concentration in our present study makes our result more precise than the previous report. Our in vitro and in vivo data indicate that an individual carrying CYP2C9*13 allele exhibits a more defective catalytic activity than that of CYP2C9*3 allele carriers, which is well in accord with the previous report (Choi et al., 2012) .
Previously reported CYP2C9*16, *19, *27, *29, and *34 alleles showed different impact on enzymatic activities. CYP2C9*16 and *19 had apparently defective effects in tolbutamide metabolism both in vitro and in vivo, whereas CYP2C9*27 and *29 exhibited a slight increase in catalytic activities toward tolbutamide when expressed in COS-7 cells and heterozygous carriers of CYP2C9*27 and *29 showed similar kinetic parameters as wild-type. We have previously reported that five alleles had relatively higher frequencies in Chinese population, which includes CYP2C9*2(0.0014), CYP2C9*3(0.0294), CYP2C9*13(0.0016), CYP2C9*16(0.0019), CYP2C9*27(0.0012), and CYP2C9*29(0.0019) (Dai et al., 2014b) . Combined with the functional analysis data, our present data suggested that CYP2C9*16 was another important defective CYP2C9 allele for Chinese Han individuals, except for the commonly studied alleles *2, *3, and *13. Maekawa et al. (2009) reported that recombinant microsome of CYP2C9*34 had no substantial effect on the metabolism of diclofenac, losartan, and glimepiride. However, in the present study, CYP2C9*34 exhibited decreased catalytic activity for tolbutamide in COS-7 cells, which is consistent with activity in vivo. Western blotting result indicated that expression of CYP2C9*34 in COS-7 cells lowered, and this may partially explain its defective effect on metabolic activity of enzyme. When expressed in insect microsomes, variant CYP2C9*34 also exhibited significantly decreased enzymatic activities toward tolbutamide (Dai et al., 2013) , glimepiride (Dai et al., 2014a) , and losartan (Wang et al., 2014) . Our in vitro and in vivo data inferred that CYP2C9*34 can be regarded as one defective allele.
For the newly found allelic variants, CYP2C9*42,*45,*46, and *48 showed defects in enzymatic activities. As shown in Fig. 1B and Table 2 , CYP2C9*42 and *45 were the most defective in metabolizing tolbutamide in COS-7 cells, with 99.18% and 99.68% decreases in clearance, respectively. Similarly, heterozygotes of CYP2C9*42 and *45 had apparent deficiency in metabolizing tolbutamide in vivo with a much longer t 1/2 and decreased clearance values compared with wild-type. In vitro data showed that CYP2C9*46 and *48 had modest deficiency in metabolizing tolbutamide in COS-7 cells. Heterozygote of Table 3 , exhibited the most defective effect in all tested heterozygotes. The in vivo outcome of CYP2C9*48 was confusing, and the reason of the discrepancy remained unknown. The analysis showed that in vivo and in vitro catalysis was well correlated, except CYP2C9*48.
In this study, CYP2C9*40 and *41 showed apparently increased enzymatic activities in COS-7 cells toward tolbutamide, which is in accordance with those observed for diclofenac (Dai et al., 2014b) . However, when expressed in insect microsomes, CYP2C9*40 exhibited decreased activity toward tolbutamide and losartan while showing similar activity to the second generation sulphonylurea-type antidiabetic drug glimepiride. CYP2C9*41 exhibited lower metabolic activities toward all these three substrates (Dai et al., 2013 (Dai et al., , 2014a Wang et al., 2014) . Thus, heterozygotes of CYP2C9*40 and CYP2C9*41 had equivalent activities toward tolbutamide in vivo. We believe that different protein expression system expressed CYPs with different protein conformation characteristics, thus exhibiting different catalytic activities toward same substrate. Compared with insect microsome expression system, mammalian cells have adequate endogenous NADPH-CYP oxidoreductase and cytochrome b5 levels to support CYP activities and are much closer to the native state of the CYP protein (Hiratsuka, 2012; Dai et al., 2014b) . Correlation analysis also confirmed this, in which data obtained in COS-7 cells are much closer to that observed in vivo.
Drawn from above, CYP2C9 enzymes expressed in COS-7 cells, to a great extent, represented its activity in vivo. However, the expression of double chromosomes would undermine its effect, and the complexity of in vivo ADME brought variables into in vitro/in vivo prediction.
The urinary measurement of tolbutamide metabolism was controversial (Veronese et al., 1993; Lee et al., 2002) . It has been demonstrated that the variability observed in urinary excretion of tolbutamide was much greater than that of two metabolites because urinary concentrations of two metabolites were much higher than those of unchanged tolbutamide , which made the amount of urinary 4-hydroxytolbutamide and carboxytolbutamide less variable than tolbutamide metabolic ratio (amount of the metabolites in urine/ amount of tolbutamide in urine). In our investigation, urinary excretion of two metabolites of tolbutamide in 0-to 24-hour interval was chosen and estimated. As shown in Fig. 6, significant decrease was observed between the CYP2C9*1/*1 and CYP2C9*1/*3 subjects. For other subjects, no statistical results were obtained because only one or two subjects were involved for one genotype. These data demonstrated that poor metabolizers tended to excrete less tolbutamide metabolites than extensive metabolizers.
The gene-response effect of tolbutamide was controversial as well (Kirchheiner et al., 2002; Shon et al., 2002; Chen et al., 2005) , in which positive or negative results were reported. In our investigation, statistically significant differences of delta blood glucose were only observed at the time points of 0.5 hour and 4.5 hours, indicating that the gene-response effect of tolbutamide, to some degree, may be more related to fasting blood glucose.
In summary, we identified 13 variations of CYP2C9 in its catalytic activities both in vitro and in vivo using tolbutamide as probe drug, including 7 previously reported variations and 6 newly found variations in Chinese population. Our data indicate that most of these mutations in CYP2C9 gene could significantly impair the catalytic activity of enzyme both in vitro and in vivo. Enzymes expressed in COS-7 cells, to an extent, well presented the enzymatic activity in vivo. Our data provide fundamental information on these allelic variants and could be relevant for the future personalized medicine in China. However, further clinical studies must be carried out in the future to precisely evaluate the effects of variations on CYP2C9 enzymatic activities in vivo because only one heterozygous carrier for each novel allele was included in the current pharmacokinetics study. Fig. 7 . (A) Average serum glucose concentration-time profiles after single oral administration of 75 g dextrose in seven normal healthy subjects with CYP2C9*1/*1 (j) (n = 7) genotypes and seven subjects with CYP2C9*1/*3 (d) (n = 7) genotypes. (B) Average delta serum glucose level from the baseline measured before oral intake of 75 g dextrose in subjects with CYP2C9*1/*1 (j) (n = 7) and CYP2C9*1/*3 (d) (n = 7) genotypes. 
